Indeed, Calais et al. [18] showed that a change in management was seen in 54 out of 101 (53%) patients who underwent 68Ga-PSMA PET/CT for BCR after curative therapy for PCa. The gene discussed is FOLH1; the disease is posterior cortical atrophy.